Automate Your Wheel Strategy on EVOK
With Tiblio's Option Bot, you can configure your own wheel strategy including EVOK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EVOK
- Rev/Share 5.0114
- Book/Share 1.7134
- PB 2.9562
- Debt/Equity 1.1724
- CurrentRatio 1.3709
- ROIC -0.5619
- MktCap 7893600.0
- FreeCF/Share -1.4183
- PFCF -2.1798
- PE -2.4027
- Debt/Assets 0.3193
- DivYield 0
- ROE -0.9948
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
MAI Capital Management Announces Strategic Partnership with Evoke Advisors
Published: August 27, 2025 by: Business Wire
Sentiment: Neutral
CLEVELAND & LOS ANGELES--(BUSINESS WIRE)--MAI Capital Management strategically partners with Evoke Advisors. Together, the firm will manage approximately $60 billion across over 30 offices.
Read More
William Hill owner Evoke falls at the first-quarter update
Published: March 26, 2025 by: Proactive Investors
Sentiment: Negative
Evoke PLC (LSE:EVOK) shares plummeted 18% after the William Hill owner reported annual results in line with expectations but revealed slower growth at the start of 2025. Results for the past calendar year showed revenues up 3% to £1.75 billion and reported losses before tax more than tripling to £191.4 million from £65.2 million the previous year.
Read More
About Evoke Pharma, Inc. (EVOK)
- IPO Date 2013-09-25
- Website https://www.evokepharma.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Matthew J. D'Onofrio MBA
- Employees 3